{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:04Z","timestamp":1789056424990,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"DOI":"10.1038\/s41417-026-01080-1","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:18:07Z","timestamp":1789053487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical translation of senescence-related pan-cancer multi-omics: tools for assessment and immunotherapy prediction"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8736-1172","authenticated-orcid":false,"given":"Xin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Jian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"1080_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"1080_CR2","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41571-022-00668-4","volume":"19","author":"CA Schmitt","year":"2022","unstructured":"Schmitt CA, Wang B, Demaria M. Senescence and cancer - role and therapeutic opportunities. Nat Rev Clin Oncol. 2022;19:619\u201336.","journal-title":"Nat Rev Clin Oncol"},{"key":"1080_CR3","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1126\/science.adj7050","volume":"384","author":"JP de Magalh\u00e3es","year":"2024","unstructured":"de Magalh\u00e3es JP. Cellular senescence in normal physiology. Science. 2024;384:1300\u20131.","journal-title":"Science"},{"key":"1080_CR4","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1093\/nar\/gkp533","volume":"37","author":"R Zhou","year":"2009","unstructured":"Zhou R, Han L, Li G, Tong T. Senescence delay and repression of p16INK4a by Lsh via recruitment of histone deacetylases in human diploid fibroblasts. Nucleic Acids Res. 2009;37:5183\u201396.","journal-title":"Nucleic Acids Res"},{"key":"1080_CR5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1101\/gad.331272.119","volume":"34","author":"MG Vizioli","year":"2020","unstructured":"Vizioli MG, Liu T, Miller KN, Robertson NA, Gilroy K, Lagnado AB, et al. Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence. Genes Dev. 2020;34:428\u201345.","journal-title":"Genes Dev"},{"key":"1080_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46769-9","volume":"15","author":"D Maggiorani","year":"2024","unstructured":"Maggiorani D, Le O, Lisi V, Landais S, Moquin-Beaudry G, Lavall\u00e9e VP, et al. Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment. Nat Commun. 2024;15:2435.","journal-title":"Nat Commun"},{"key":"1080_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac118","volume":"23","author":"X Wang","year":"2022","unstructured":"Wang X, Ma L, Pei X, Wang H, Tang X, Pei JF, et al. Comprehensive assessment of cellular senescence in the tumor microenvironment. Brief Bioinform. 2022;23:bbac118.","journal-title":"Brief Bioinform"},{"key":"1080_CR8","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12929-023-00915-5","volume":"30","author":"Z Wu","year":"2023","unstructured":"Wu Z, Uhl B, Gires O, Reichel CA. A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence. J Biomed Sci. 2023;30:21.","journal-title":"J Biomed Sci"},{"key":"1080_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-01990-9","volume":"21","author":"RA Avelar","year":"2020","unstructured":"Avelar RA, Ortega JG, Tacutu R, Tyler EJ, Bennett D, Binetti P, et al. A multidimensional systems biology analysis of cellular senescence in aging and disease. Genome Biol. 2020;21:91.","journal-title":"Genome Biol"},{"key":"1080_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.70011","volume":"4","author":"B Ye","year":"2025","unstructured":"Ye B, Fan J, Xue L, Zhuang Y, Luo P, Jiang A, et al. iMLGAM: integrated machine learning and genetic algorithm-driven multiomics analysis for pan-cancer immunotherapy response prediction. Imeta. 2025;4:e70011.","journal-title":"Imeta"},{"key":"1080_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906194","volume":"12","author":"AL Sorteberg","year":"2022","unstructured":"Sorteberg AL, Halipi V, Wickstr\u00f6m M, Shirazi FS. The cyclin dependent kinase inhibitor p21(Cip1\/Waf1) is a therapeutic target in high-risk neuroblastoma. Front Oncol. 2022;12:906194.","journal-title":"Front Oncol"},{"key":"1080_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934243","volume":"13","author":"C Lu","year":"2022","unstructured":"Lu C, Wang Y, Nie L, Chen L, Li M, Qing H, et al. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy\/chemotherapy of clear cell renal cell carcinoma. Front Immunol. 2022;13:934243.","journal-title":"Front Immunol"},{"key":"1080_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","volume":"35","author":"J Vivian","year":"2017","unstructured":"Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, et al. Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 2017;35:314\u20136.","journal-title":"Nat Biotechnol"},{"key":"1080_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/ni.2789","volume":"15","author":"S Li","year":"2014","unstructured":"Li S, Rouphael N, Duraisingham S, Romero-Steiner S, Presnell S, Davis C, et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol. 2014;15:195\u2013204.","journal-title":"Nat Immunol"},{"key":"1080_CR15","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1038\/s41596-021-00505-5","volume":"16","author":"J Kohli","year":"2021","unstructured":"Kohli J, Wang B, Brandenburg SM, Basisty N, Evangelou K, Varela-Eirin M, et al. Algorithmic assessment of cellular senescence in experimental and clinical specimens. Nat Protoc. 2021;16:2471\u201398.","journal-title":"Nat Protoc"},{"key":"1080_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","volume":"6","author":"K Ellrott","year":"2018","unstructured":"Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 2018;6:271\u2013.e7.","journal-title":"Cell Syst"},{"key":"1080_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173:321\u2013.e10.","journal-title":"Cell"},{"key":"1080_CR18","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.","journal-title":"Nucleic Acids Res"},{"key":"1080_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22560-y","volume":"12","author":"K Chatsirisupachai","year":"2021","unstructured":"Chatsirisupachai K, Lesluyes T, Paraoan L, Van Loo P, de Magalh\u00e3es JP. An integrative analysis of the age-associated multi-omic landscape across cancers. Nat Commun. 2021;12:2345.","journal-title":"Nat Commun"},{"key":"1080_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.","journal-title":"Genome Biol"},{"key":"1080_CR21","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2018.08.019","volume":"34","author":"J Yuan","year":"2018","unstructured":"Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, et al. Integrated analysis of genetic ancestry and genomic alterations across cancers. Cancer Cell. 2018;34:549\u2013.e9.","journal-title":"Cancer Cell"},{"key":"1080_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46413-6","volume":"15","author":"Z Zhong","year":"2024","unstructured":"Zhong Z, Hou J, Yao Z, Dong L, Liu F, Yue J, et al. Domain generalization enables general cancer cell annotation in single-cell and spatial transcriptomics. Nat Commun. 2024;15:1929.","journal-title":"Nat Commun"},{"key":"1080_CR23","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s42003-025-07942-y","volume":"8","author":"Q Yu","year":"2025","unstructured":"Yu Q, Li YY, Chen Y. scMalignantFinder distinguishes malignant cells in single-cell and spatial transcriptomics by leveraging cancer signatures. Commun Biol. 2025;8:504.","journal-title":"Commun Biol"},{"key":"1080_CR24","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell. 2018;175:984\u2013.e24.","journal-title":"Cell"},{"key":"1080_CR25","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med. 2019;25:1251\u20139.","journal-title":"Nat Med"},{"key":"1080_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"},{"key":"1080_CR27","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25:1916\u201327.","journal-title":"Nat Med"},{"key":"1080_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct immune cell populations define response to anti-PD-1 Monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy. Cancer Cell. 2019;35:238\u2013.e6.","journal-title":"Cancer Cell"},{"key":"1080_CR29","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","volume":"171","author":"N Riaz","year":"2017","unstructured":"Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell. 2017;171:934\u2013.e16.","journal-title":"Cell"},{"key":"1080_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207\u201311.","journal-title":"Science"},{"key":"1080_CR31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"1080_CR32","doi-asserted-by":"publisher","first-page":"e1002309","DOI":"10.1371\/journal.pmed.1002309","volume":"14","author":"A Snyder","year":"2017","unstructured":"Snyder A, Nathanson T, Funt SA, Ahuja A, Buros NJ, Hellmann MD, et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Med. 2017;14:e1002309.","journal-title":"PLoS Med"},{"key":"1080_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41591-019-0349-y","volume":"25","author":"J Zhao","year":"2019","unstructured":"Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25:462\u20139.","journal-title":"Nat Med"},{"key":"1080_CR34","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449\u201358.","journal-title":"Nat Med"},{"key":"1080_CR35","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun DA, Hou Y, Bakouny Z, Ficial M, Sant AM, Forman J, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26:909\u201318.","journal-title":"Nat Med"},{"key":"1080_CR36","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"1080_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48\u201361.","journal-title":"Cell"},{"key":"1080_CR38","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"1080_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa345","volume":"22","author":"M Ju","year":"2021","unstructured":"Ju M, Bi J, Wei Q, Jiang L, Guan Q, Zhang M, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform. 2021;22:bbaa345.","journal-title":"Brief Bioinform"},{"key":"1080_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, M\u00fcller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 2020;10:232\u201353.","journal-title":"Cancer Discov"},{"key":"1080_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18546-x","volume":"11","author":"D Xiong","year":"2020","unstructured":"Xiong D, Wang Y, You M. A gene expression signature of TREM2(hi) macrophages and \u03b3\u03b4 T cells predicts immunotherapy response. Nat Commun. 2020;11:5084.","journal-title":"Nat Commun"},{"key":"1080_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.758288","volume":"12","author":"M Yan","year":"2021","unstructured":"Yan M, Hu J, Ping Y, Xu L, Liao G, Jiang Z, et al. Single-cell transcriptomic analysis reveals a tumor-reactive T cell signature associated with clinical outcome and immunotherapy response in melanoma. Front Immunol. 2021;12:758288.","journal-title":"Front Immunol"},{"key":"1080_CR43","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.cell.2018.03.026","volume":"173","author":"SA Shukla","year":"2018","unstructured":"Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, et al. Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade. Cell. 2018;173:624\u2013.e8.","journal-title":"Cell"},{"key":"1080_CR44","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018;24:1545\u20139.","journal-title":"Nat Med"},{"key":"1080_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41525-021-00169-w","volume":"6","author":"C Cui","year":"2021","unstructured":"Cui C, Xu C, Yang W, Chi Z, Sheng X, Si L, et al. Ratio of the interferon-\u03b3 signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. NPJ Genom Med. 2021;6:7.","journal-title":"NPJ Genom Med"},{"key":"1080_CR46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1126\/science.1140735","volume":"319","author":"TD Halazonetis","year":"2008","unstructured":"Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319:1352\u20135.","journal-title":"Science"},{"key":"1080_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/path.6164","volume":"260","author":"K Evangelou","year":"2023","unstructured":"Evangelou K, Belogiannis K, Papaspyropoulos A, Petty R, Gorgoulis VG. Escape from senescence: molecular basis and therapeutic ramifications. J Pathol. 2023;260:649\u201365.","journal-title":"J Pathol"},{"key":"1080_CR48","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou YTH, et al. The immune landscape of cancer. Immunity. 2018;48:812\u2013.e14.","journal-title":"Immunity"},{"key":"1080_CR49","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","volume":"66","author":"M Arnold","year":"2017","unstructured":"Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683\u201391.","journal-title":"Gut"},{"key":"1080_CR50","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.trecan.2020.05.004","volume":"6","author":"B Wang","year":"2020","unstructured":"Wang B, Kohli J, Demaria M. Senescent cells in cancer therapy: friends or foes. Trends Cancer. 2020;6:838\u201357.","journal-title":"Trends Cancer"},{"key":"1080_CR51","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1080_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc2772","volume":"10","author":"M Collado","year":"2010","unstructured":"Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10:51\u201357.","journal-title":"Nat Rev Cancer"},{"key":"1080_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112679","volume":"405","author":"ER Stead","year":"2021","unstructured":"Stead ER, Bjedov I. Balancing DNA repair to prevent ageing and cancer. Exp Cell Res. 2021;405:112679.","journal-title":"Exp Cell Res"},{"key":"1080_CR54","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.tig.2020.10.003","volume":"37","author":"AV Nesta","year":"2021","unstructured":"Nesta AV, Tafur D, Beck CR. Hotspots of human mutation. Trends Genet. 2021;37:717\u201329.","journal-title":"Trends Genet"},{"key":"1080_CR55","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41573-024-01074-4","volume":"24","author":"D McHugh","year":"2025","unstructured":"McHugh D, Dur\u00e1n I, Gil J. Senescence as a therapeutic target in cancer and age-related diseases. Nat Rev Drug Discov. 2025;24:57\u201371.","journal-title":"Nat Rev Drug Discov"},{"key":"1080_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02096-7","volume":"23","author":"Z Dong","year":"2024","unstructured":"Dong Z, Luo Y, Yuan Z, Tian Y, Jin T, Xu F. Cellular senescence and SASP in tumor progression and therapeutic opportunities. Mol Cancer. 2024;23:181.","journal-title":"Mol Cancer"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01080-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:18:08Z","timestamp":1789053488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01080-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":56,"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01080-1","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study is based on publicly available data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO) databases, which have been de-identified and released with appropriate ethical approvals from their respective institutions. All data used herein are openly accessible and comply with the principles of the Declaration of Helsinki. No direct human or animal subjects were involved in this research, and thus, additional ethical approval was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}